Results 291 to 300 of about 458,215 (302)

Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event

New England Journal of Medicine, 2003
Hanno Ulmer, Florian Deisenhammer, Markus Reindl   +2 more
exaly  

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

New England Journal of Medicine, 2012
Robert J Fox, J Theodore Phillips, Michael Hutchinson   +2 more
exaly  

Relapses and Progression of Disability in Multiple Sclerosis

New England Journal of Medicine, 2000
Christian Confavreux, Sandra Vukusic, C Confavreux   +2 more
exaly  

Inflammatory Cortical Demyelination in Early Multiple Sclerosis

New England Journal of Medicine, 2011
Claudia F Lucchinetti, Hans Lassmann, Wolfgang Bruck   +2 more
exaly  

Multiple Sclerosis

The American Journal of Nursing, 1936
openaire   +2 more sources

The multiple sclerosis market

Nature Reviews Drug Discovery, 2017
exaly  

MULTIPLE SCLEROSIS

The Lancet, 1971
openaire   +2 more sources

FDA reversal sends mixed message to multiple sclerosis community

Nature Reviews Drug Discovery, 2014
exaly  

Multiple sclerosis

Current Opinion in Immunology, 1988
openaire   +2 more sources

Multiple Sclerosis

Archives of Neurology, 1998
openaire   +3 more sources